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Dr. Favalli, et al reply
To the Editor:
We thank Dr. So, et al1 for the interest in our letter2 and for sharing the 
results about the coronavirus disease 2019 (COVID-19) in patients with 
systemic lupus erythematosus (SLE) in Hong Kong1. 
	 We	 agree	 that	 the	 quantification	 of	 the	 risk	 of	 infection	with	 severe	
acute respiratory coronaviruses-2 (SARS-CoV-2) in patients with SLE is 
a major concern. This is even more true in light of the recently published 
data from Mathian and colleagues3, who analyzed the course of COVID-19 
in a case series of 17 patients with SLE. Of these, 13 (76%) developed 
interstitial pneumonia, complicated by respiratory failure in 11 (65%) and 
acute respiratory distress syndrome in 5 (29%). Moreover, 3 patients had 
acute renal failure, with 2 patients requiring hemodialysis. The results of 
this	 analysis	 first	 demonstrated	 that	 the	 clinical	 course	 of	COVID-19	 in	
patients with SLE seems to be particularly unfavorable and facilitated by 
multiorgan involvement and the several comorbidities often complicating 
this complex autoimmune disease. Because of this evidence, it becomes 
even	more	crucial	to	define	whether	patients	with	SLE	are	burdened	with	an	
increased	risk	of	contracting	COVID-19	to	efficiently	establish	a	prophy-
laxis	 program.	Another	 still	 critical	 point	 is	 the	 definition	 of	 the	 role	 of	
chloroquine and hydroxychloroquine in the prevention and treatment of 
SARS-CoV-2 infection. In fact, after the in vitro demonstration of anti-
malarials’ ability to interfere with the endocytosis of the virus within the 
target	cells	and	the	first	favorable	in vivo results that led to their inclusion 
in COVID-19 management protocols worldwide4, the most recent clinical 
studies have provided controversial results that leave many doubts about 
the	real	efficacy	and	safety	profile	of	these	drugs	for	this	indication5. The 
data we recently published on the frequency of COVID-19 in connective 
tissue diseases2, investigated through an exploratory survey to evaluate 
the incidence and course of COVID-19, included a portion of patients 
with SLE, which has further increased over time as our data collection 
progressed. In the most recent update, the group under review included 
65	 patients	with	SLE,	 none	 of	whom	 received	 a	 diagnosis	 of	 confirmed	
COVID-196. Conversely, in a cohort of 165 patients with SLE investigated 
by telemedicine in another rheumatology unit in Lombardy, 4 patients were 
diagnosed	with	COVID-19	 confirmed	by	 swab	 and	 8	with	 highly	 suspi-
cious COVID-19 (at least 3 out of 4 symptoms among fever, dyspnea, 
cough, and dysgeusia/anosmia plus established contact with a COVID-19 
patient, no swab test performed)7. However, these study populations are 
still	too	limited	in	number	to	draw	definitive	conclusions,	and	larger	cohort	
studies are certainly warranted to address the issue. With this in mind, the 
COVID-19 Global Rheumatology Alliance recently launched a worldwide 
register for patients with rheumatic diseases with COVID-19, which may 
decisively	 contribute	 with	 additional	 findings.	 Preliminary	 data	 recently	
published	on	110	patients	also	included	19	SLE	cases,	confirming	that	the	
infection can certainly affect this type of patients as well8. 
 It is very likely that patients with SLE are exposed to at least the same 
risk as the general population of acquiring COVID-19; however, they 
generally have a more unfavorable clinical course. 
ENNIO GIULIO FAVALLI, MD, Division of Clinical Rheumatology, 
Azienda	Socio	Sanitaria	Territoriale	(ASST)	Gaetano	Pini-CTO	Institute;	
ELENA	AGAPE,	MD, Division of Clinical Rheumatology, ASST Gaetano 
Pini-CTO	Institute;	ROBERTO	CAPORALI,	MD, Division of Clinical 
Rheumatology,	ASST	Gaetano	Pini-CTO	Institute,	and	Department	of	
Clinical Sciences and Community Health, Research Center for Adult and 
Pediatric	Rheumatic	Diseases,	Università	degli	Studi	di	Milano,	Milan,	
Italy. The current analysis is part of a project to collect observational data 
from	rheumatological	patients	followed	at	the	ASST	Gaetano	Pini-CTO.	
The	project	was	approved	by	the	Ethics	Committee	of	the	Gaetano	Pini	
Institute with approval number 141/2010. All included patients gave 
informed consent to participate in the data collection. Address corre-
spondence to Dr. E.G. Favalli, Division of Clinical Rheumatology, ASST 
Gaetano	Pini-CTO	Institute,	Via	Gaetano	Pini	9,	20122	Milan,	Italy.	
E-mail: enniofavalli@me.com
REFERENCES
 1. So H, Mak JW, Tam LS. No systemic lupus erythematosus with 
COVID-19 in Hong Kong: the effect of masking? J Rheumatol 
2020;47:xxxxxx.
 2. Favalli EG, Agape E, Caporali R. Incidence and clinical course of 
COVID-19 in patients with connective tissue diseases: a descriptive 
observational analysis. J Rheumatol 2020 May 15 (E-pub ahead of 
print). 
 3. Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, 
Amador-Borrero B, et al. Clinical course of coronavirus disease 
2019 (COVID-19) in a series of 17 patients with systemic lupus 
erythematosus under long-term treatment with hydroxychloroquine. 
Ann	Rheum	Dis	2020;79:837-9.	
 4. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has 
shown apparent efficacy in treatment of COVID-19 associated 
pneumonia in clinical studies. Biosci Trends 2020;14:72-3.
	 5.	 Mehra	MR,	Desai	SS,	Ruschitzka	F,	Patel	AN.	Hydroxychloroquine	
or chloroquine with or without a macrolide for treatment of 
COVID-19: a multinational registry analysis. Lancet 2020 May 22 
(E-pub ahead of print).
 6. Favalli EG, Gerosa M, Murgo A, Caporali R. Are patients with 
systemic lupus erythematosus at increased risk for COVID-19? Ann 
Rheum Dis 2020 May 25 (E-pub ahead of print).
 7. Cassione EB, Zanframundo G, Biglia A, Codullo V, Montecucco 
C, Cavagna L. COVID-19 infection in a northern-Italian cohort 
of systemic lupus erythematosus assessed by telemedicine. Ann 
Rheum Dis 2020 May 12 (E-pub ahead of print).
	 8.	 Gianfrancesco	MA,	Hyrich	KL,	Gossec	L,	Strangfeld	A,	Carmona	
L, Mateus EF, et al. Rheumatic disease and COVID-19: initial 
data from the COVID-19 Global Rheumatology Alliance provider 
registries. Lancet Rheumatol 2020 Apr 16 (E-pub ahead of print).
First Release June 15 2020; J Rheumatol 2020;47:xxxx; 
doi:10.3899/jrheum.200723
 Rheumatology
The Journal of on July 13, 2020 - Published by www.jrheum.orgDownloaded from 
